Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a ...

Arrival of biosimilar competition in the U.S. has so far not put a dent in Humira's sales, as maker AbbVie responded by hiking its discounts and rebates paid to insurers and pharmacy benefit managers.